MTOR and renal cell carcinoma: Recently, molecularly targeted therapies, such as VEGF signaling inhibitors (sorafenib, sunitinib, bevacizumab) and mTOR inhibitors (everolimus, temsirolimus) have become FDA-approved as front-line therapy for RCC patients [28].